| Project/Area Number |
17591431
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Osaka City University |
|---|
Principal Investigator |
KUBO Shoji Osaka City University, Graduate School of Medicine Department of Hepato-Biliary-Pancreatic Surgery, Associated Professor (80221224)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NISHIGUCHI Shuhei Hyogo Medical College, Department of Hepatology, Professor (10192246)
TANAKA Hiromu Osaka City University, Graduate School of Medicine Department of Hepato-Biliary-Pancreatic Surgery, Lecturer (90275256)
|
|---|
| Project Period (FY) |
2005 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥3,280,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥180,000)
Fiscal Year 2007: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2006: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 2005: ¥1,700,000 (Direct Cost: ¥1,700,000)
|
|---|
| Keywords | Hepatocellular carcinoma / Hepatitis B virus gene / Hepatitis C virus / Cholangiocarcinoma / Hepatic progenitor cell / Methylation of DNA / high mobility group A2 / Interferon |
|---|
| Research Abstract |
HBV DNA was integrated at random sites of human DNA, and the MLL2 gene was cone of the targets for integration. Our results suggest that HBV DNA might modulate human genes near integration sites, followed by integration site - specific expression of such genes during hepatocarcinogenesis.
The expression and alternation of high mobility group A2 (HMGA2) were investigated by RT-PCR using cancerous tissues and noncancerous tissues in patients with hepatocellular carcinoma. The expression was found in one-third of cancerous tissues and the prevalence increased in less differentiated carcinoma. The alternation also increased in poorly differentiated hepatocellular carcinoma. The results indicate the expression and alternation of HMGA2 correlated with the development of hepatocellular carcinoma.
Although high concentration of serum cytokeratin-19 fragment (CYFRA 21-1) were often detected in patients with a tumor diameter greater than 5 cm of tumor thrombus in the major portal vein, CYFRA 21\1 is not a useful diagnostic tool for hepatocellular carcinoma because of its low sensitivity.
In patients who underwent liver resection for hepatocellular carcinoma, the results were superior in patients who respond interferon therapy than in patients who did not respond the therapy or who lacks the therapy. Interferon therapy can improve postoperative outcomes because of suppression of recurrence and preventing prognosis of cirrhosis, especially when interferon therapy has controlled their active hepatitis.
|
